Early PCSK9 inhibitor after heart attack for other artery blockages
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether starting a cholesterol-lowering drug called a PCSK9 inhibitor soon after a heart attack can help prevent future blockages. If you had a heart attack, received a stent, and have other arteries with minor blockages, this trial may be for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You were hospitalized for a heart attack and had a stent placed in the blocked artery.
- You have at least two other heart arteries with mild to moderate blockages (40-70% narrowed).
- You have not taken a PCSK9 inhibitor (like Repatha or Praluent) in the past 3 months.
- You do not have other serious health conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
This trial looks at when and how to use cholesterol-lowering treatment soon after a heart attack. It may help people lower LDL (“bad” cholesterol) safely in the first days after an acute event.
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
This trial tests whether a drug called a PCSK9 inhibitor can reduce harmful inflammation and organ damage in people recovering from coronary artery bypass surgery (CABG). If you are scheduled for bypass surgery within a month, this study may be an option for you.
This trial tests whether a PCSK9 inhibitor (a drug that lowers cholesterol) can help people who recently had a stroke caused by narrowing of an artery inside the skull. It aims to see if the drug can prevent more strokes and improve recovery.
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
Hear when a new Acute Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.